Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

KP-100LI

Phase 3Small molecule

KKringle Pharma, Inc.

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

ScarActive, not recruiting

ScarPhase 3

Active, not recruiting

Timeline

Expected Milestones

Q1 2027

Phase 3Active, not recruiting

Scar

NCT05627648

Clinical

Trials by Indication[1]

Scar1 trial

A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Confirmatory Study For Intracordal Administration Of KP-100LI In Patients With Vocal Fold Scar

Active, not recruiting·KKringle Pharma, Inc.·Phase 3·NCT05627648·62 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for KP-100LI. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — KP-100LI compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for KP-100LI. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Kringle Pharma, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: KKringle Pharma, Inc.

Related News